Volume 29, Issue 3
DOI: 10.24205/03276716.2020.734
Effects of diammonium glycyrrhizinate on serum inflammatory factors and peripheral blood T lymphocytes in patients with stable chronic obstructive pulmonary disease
Abstract
Objective: To evaluate the influence of diammonium glycyrrhizinate on serum inflammatory factors and peripheral blood T lymphocytes in patients with chronic obstructive pulmonary disease (COPD) in the stable phase.
Methods: A total of 244 cases admitted from January 2015 to June 2019 were divided into control and observation groups (n=122) randomly. The control group received Western medicine therapy and the observation group was further given diammonium glycyrrhizinate capsules for three months. Their therapeutic effects, pulmonary function indices, serum inflammatory factors and peripheral blood T lymphocytes were compared. Results: After treatment, the overall effective rates of observation and control groups were 90.68% and 75.00%, respectively (χ2=10.146, P=0.001). FEV1, FVC and FEV1/FVC of both groups significantly increased, especially in observation group (P<0.05). Serum CRP, TNF-α and IL-6 levels significantly decreased, particularly in observation group (P<0.05).
The two groups had significantly different CD8 , CD4 and CD3 cell counts as well as CD4 /CD8 cell ratio (P<0.05). The incidence rates of adverse drug reactions in control and observation groups were 6.56% and 9.68%, respectively (P>0.05).
Conclusion: For patients with stable COPD, routine treatment plus diammonium glycyrrhizinate can enhance therapeutic effects, improve pulmonary function, alleviate inflammation and boost immune function while hardly inducing adverse drug reactions.
Keywords
Diammonium glycyrrhizinate; chronic obstructive pulmonary disease; inflammatory factor; immune function